Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial

Clinical trial NCT05947500 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05947500
Sponsor: National Cancer Institute (NCI)
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8 Locally Advanced Merkel Cell Carcinoma Metastatic Merkel Cell Carcinoma Refractory Merkel Cell Carcinoma Unresectable Merkel Cell Carcinoma

Start date: 2024-05-21
Primary completion: 2028-01-01
Enrollment: 50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.